1. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Issue 33 (20th November 2021) Authors: Pal, Sumanta K.; McGregor, Bradley; Suárez, Cristina; Tsao, Che-Kai; Kelly, William; Vaishampayan, Ulka; Pagliaro, Lance; Maughan, Benjamin L.; Loriot, Yohann; Castellano, Daniel; Srinivas, Sandy; McKay, Rana R.; Dreicer, Robert; Hutson, Thomas; Dubey, Sarita; Werneke, Scott; Panneerselvam, Ashok... Journal: Journal of clinical oncology Issue: Volume 39:Issue 33(2021) Page Start: 3725 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Issue 7 (July 2022) Authors: Agarwal, Neeraj; McGregor, Bradley; Maughan, Benjamin L; Dorff, Tanya B; Kelly, William; Fang, Bruno; McKay, Rana R; Singh, Parminder; Pagliaro, Lance; Dreicer, Robert; Srinivas, Sandy; Loriot, Yohann; Vaishampayan, Ulka; Goel, Sanjay; Curran, Dominic; Panneerselvam, Ashok; Schwickart, Martin; Ch... Journal: Lancet oncology Issue: Volume 23:Issue 7(2022) Page Start: 899 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗